Literature DB >> 11684940

Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.

C Delaugerre1, M A Valantin, M Mouroux, M Bonmarchand, G Carcelain, C Duvivier, R Tubiana, A Simon, F Bricaire, H Agut, B Autran, C Katlama, V Calvez.   

Abstract

Antiretroviral treatment interruption in 20 extensively pre-treated HIV-1 patients with treatment failure led to genotype viral reversion of at least one class of drug-mutation resistance in half of the patients. The only predictive factor of reversion was found to be the duration of interruption. The outgrowth of residual wild-type virus seems not to be a true genetic reversion because drug mutations are detected rapidly at salvage therapy re-initiation.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11684940     DOI： 10.1097/00002030-200111090-00016

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  15 in total

1.  Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.

Authors:  Marc Wirden; Constance Delaugerre; Anne Genevieve Marcelin; Nadine Ktorza; Hocine Ait Mohand; Stephanie Dominguez; Luminita Schneider; Jade Ghosn; Michele Pauchard; Dominique Costagliola; Christine Katlama; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 2.  Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.

Authors:  Mark A Boyd; Andrew M Hill
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.

Authors:  Elias K Halvas; Grace M Aldrovandi; Peter Balfe; Ingrid A Beck; Valerie F Boltz; John M Coffin; Lisa M Frenkel; J Darren Hazelwood; Victoria A Johnson; Mary Kearney; Andrea Kovacs; Daniel R Kuritzkes; Karin J Metzner; Dwight V Nissley; Marek Nowicki; Sarah Palmer; Rainer Ziermann; Richard Y Zhao; Cheryl L Jennings; James Bremer; Don Brambilla; John W Mellors
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

Review 4.  Approach to the treatment-experienced patient.

Authors:  Joel E Gallant
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

5.  Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Authors:  Sarah Palmer; Mary Kearney; Frank Maldarelli; Elias K Halvas; Christian J Bixby; Holly Bazmi; Diane Rock; Judith Falloon; Richard T Davey; Robin L Dewar; Julia A Metcalf; Scott Hammer; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

6.  Management of HIV-infected Patients with Multidrug-resistant Virus.

Authors:  Julio S.G. Montaner; Marianne Harris
Journal:  Curr Infect Dis Rep       Date:  2002-06       Impact factor: 3.725

7.  Structured Treatment Interruption: Approaches and Risks.

Authors:  Mark Dybul
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.725

8.  Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.

Authors:  Constance Delaugerre; Marie-Laure Chaix; Stephane Blanche; Josiane Warszawski; Dorine Cornet; Catherine Dollfus; Veronique Schneider; Marianne Burgard; Albert Faye; Laurent Mandelbrot; Roland Tubiana; Christine Rouzioux
Journal:  Retrovirology       Date:  2009-09-19       Impact factor: 4.602

9.  Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.

Authors:  Gustavo H Kijak; Viviana Simon; Peter Balfe; Jeroen Vanderhoeven; Sandra E Pampuro; Carlos Zala; Claudia Ochoa; Pedro Cahn; Martin Markowitz; Horacio Salomon
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway.

Authors:  Maryanne T Vahey; Zhining Wang; Zhaohui Su; Martin E Nau; Amy Krambrink; Daniel J Skiest; David M Margolis
Journal:  AIDS Res Hum Retroviruses       Date:  2008-08       Impact factor: 2.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.